Publication: Chitosan-based nanoparticles with damnacanthal suppress CRM1 expression
Issued Date
2018-12-01
Resource Type
ISSN
17921082
17921074
17921074
Other identifier(s)
2-s2.0-85055205421
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Oncology Letters. Vol.16, No.6 (2018), 7029-7034
Suggested Citation
Nadda Chaichanasak, Pleumchitt Rojanapanthu, Yongdae Yoon, Wandee Gritsanapan, Suwabun Chirachanchai, Korbtham Sathirakul, Thararat Nualsanit, Je Kyung Seong, Seung Joon Baek Chitosan-based nanoparticles with damnacanthal suppress CRM1 expression. Oncology Letters. Vol.16, No.6 (2018), 7029-7034. doi:10.3892/ol.2018.9507 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/44976
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Chitosan-based nanoparticles with damnacanthal suppress CRM1 expression
Abstract
© Chaichanasak et al. Cancer is one of the leading causes of mortality worldwide. Phytochemicals may be promising anticancer agents given their various chemical structures and diverse biological activities. Damnacanthal (DAM) is a major bioactive component of Noni, which has been investigated previously as a cancer-preventive or chemotherapeutic agent. DAM has also been reported to exhibit anti-proliferative activity in several cancer types. In the present study, it was identified that DAM downregulates chromosome maintenance protein 1 (CRM1) expression in human cancer cells. The application of chitosan-based nanoparticles (NPs) with DAM also induced CRM1 downregulation, which suggests that chitosan-based NPs may be effective vehicles for delivery of phytochemicals such as DAM. It was also identified that DAM increased the levels of the tumor suppressor non-steroidal anti-inflammatory drugs-activated gene 1 in the nucleus, thereby leading to enhanced anticancer effects. The results of the present study indicate that DAM and its nanoformulation may be a candidate anticancer drug.